EGFR targeted therapy resistance: current status, challenges, and future outlook is a research paper published in Journal of Thoracic Disease (2020). On theSindex it has a DataRank of 0.165. It has been cited 2 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R01 CA169338
NCI NIH HHS
Grant: R01 CA231300
NCI NIH HHS
Grant: R01 CA204302
NCI NIH HHS
Grant: U54 CA224081
NCI NIH HHS
Grant: R01 CA211052
National Institutes of Health
Grant: 5R01CA211052-03
Optimizing biologically-based rational polytherapy in ALK+ lung cancer
National Institutes of Health
Grant: 5R01CA169338-02
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment
National Institutes of Health
Grant: 5R01CA231300-03
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules
National Institutes of Health
Grant: 1R01CA204302-01A1
Characterization of YAP as a rational companion target in lung cancer
National Institutes of Health
Grant: 3U54CA224081-01S1
Bay Area Team Against Resistance
FWCI
0.11
Citation Percentile
0.4%
Citation Trend
Fields of Study
Keywords